Sponsor-Investigator

A sponsor-investigator is a specific FDA regulatory designation (21 CFR 312.3 for drugs/biologics; 21 CFR 812.3 for devices) for an individual -- never an institution, company, or group -- who both initiates a clinical investigation and actually conducts it, personally directing the administration, dispensing, or use of the investigational product to subjects. Because one person occupies both roles, that individual must independently satisfy the full set of sponsor obligations (21 CFR 312.50-312.59) and the full set of investigator obligations (21 CFR 312.60-312.70) under the same IND or IDE -- there is no reduced or merged standard for holding both roles at once.

ByCASRAI Editorial Board

· Last updated 18 Jul 2026

Worked examples

Is an instance

A university faculty member who designs a Phase 1 investigator-initiated trial of a repurposed drug, personally holds the IND with FDA, and also serves as the treating clinician administering the study drug to enrolled subjects is a sponsor-investigator under 21 CFR 312.3.

Is an instance

A physician who obtains an Investigational Device Exemption (IDE) for a device they invented and then personally implants it in trial subjects at their own clinic is a sponsor-investigator under 21 CFR 812.3.

Looks similar, but isn't

Not an instance

A physician who enrolls patients in a multi-site trial sponsored by a pharmaceutical company, administering the study drug under a protocol the company designed and holds the IND for, is an investigator, not a sponsor-investigator -- the company is the sponsor.

Not an instance

A university that holds institutional sponsorship of an IND on behalf of one of its faculty is not itself a sponsor-investigator -- 21 CFR 312.3 restricts the sponsor-investigator designation to an individual; an institution can be a sponsor, but not a sponsor-investigator.

A sponsor-investigator is a formally defined FDA regulatory role: a single individual who both initiates a clinical investigation and actually conducts it, combining the responsibilities of a trial sponsor and the responsibilities of an investigator in one person. It is a narrower, more specific concept than investigator-initiated study (IIS), which describes how a study is funded and originated rather than who holds which regulatory obligations.

Regulatory definition

Under 21 CFR 312.3, part of the FDA’s Investigational New Drug (IND) regulation, a sponsor-investigator is “an individual who both initiates and conducts an investigation, and under whose immediate direction the investigational drug is administered or dispensed.” The same regulation separately defines a sponsor as “a person who takes responsibility for and initiates a clinical investigation” (which may be an individual or an organization) and an investigator as “an individual who actually conducts a clinical investigation.” A sponsor-investigator is the specific case where the same person satisfies both definitions at once.

The designation is restricted to a natural person. An institution, company, or other organization cannot itself be a sponsor-investigator, even when it holds institutional sponsorship of a study on a faculty member’s behalf.

Devices: the IDE equivalent

The equivalent device regulation, 21 CFR 812.3, defines a sponsor-investigator for the Investigational Device Exemption (IDE) context as “an individual who both initiates and actually conducts, alone or with others, an investigation, that is, under whose immediate direction the investigational device is administered, dispensed, or used.” The same individual-only restriction and dual-obligation structure applies under 21 CFR Part 812.

Sponsor-investigator vs. investigator-initiated study

These two concepts are often confused because they usually co-occur, but they describe different things:

Investigator-initiated study (IIS) describes where a study’s protocol and IND/IDE sponsorship originate — from an academic investigator rather than a pharmaceutical or device company — regardless of who ends up personally treating subjects. See Investigator-Initiated Study (IIS).
Sponsor-investigator is a specific regulatory designation under 21 CFR 312.3/812.3 for the individual who holds both the sponsor role and the investigator role for that IND or IDE.

Most investigator-initiated studies do involve a sponsor-investigator, because the academic investigator who designs the study and holds the IND is typically also the person treating subjects. But the two are not synonymous: an investigator-initiated study can remain investigator-initiated even where drug supply or funding comes from a company, as long as the company has not taken over IND/IDE sponsorship — and a study can have separate sponsor and investigator individuals (for example, a department chair holding the IND while a different clinician conducts the treatment), in which case no single person is the sponsor-investigator even though the study is still investigator-initiated.

Sponsor-investigator vs. principal investigator

Every sponsor-investigator is functionally a principal investigator (PI) for the study — the individual who signs FDA Form 1572 (Statement of Investigator) and is responsible for the team’s conduct of the protocol. What distinguishes a sponsor-investigator from an ordinary PI is that the sponsor-investigator also personally holds the IND or IDE and the full set of sponsor obligations that come with it — an ordinary PI in an industry-sponsored or company-IND study has none of those sponsor duties, because the company retains them.

Dual regulatory obligations

Because a sponsor-investigator occupies both roles simultaneously, FDA does not reduce or merge the two sets of obligations under 21 CFR Part 312, Subpart D — the individual must independently satisfy both in full:

Sponsor responsibilities (21 CFR 312.50-312.59): general sponsor duties, transfer of obligations to a CRO, selecting qualified investigators and monitors, informing investigators, reviewing ongoing safety information, recordkeeping, and disposition of unused drug supply.
Investigator responsibilities (21 CFR 312.60-312.70): general investigator duties, control of the investigational drug, investigator recordkeeping and reporting, ensuring IRB review, and cooperating with FDA inspection of investigator records.

In practice this means a sponsor-investigator is accountable for IND maintenance and FDA safety reporting (the sponsor side) as well as protocol conduct, informed consent, and IRB compliance for the subjects they personally treat (the investigator side) — with no institutional sponsor standing behind them to absorb either set of duties.

Frequently asked questions

Is a sponsor-investigator the same as a principal investigator?

No. Every sponsor-investigator acts as the study’s principal investigator, but not every principal investigator is a sponsor-investigator. A PI in a company-sponsored trial does not hold the IND and is not a sponsor-investigator; only a PI who also personally holds the IND or IDE and its sponsor obligations qualifies.

Can an institution be a sponsor-investigator?

No. 21 CFR 312.3 and 21 CFR 812.3 both define the sponsor-investigator designation as an individual. An institution can be a sponsor (including on behalf of one of its investigators), but it cannot be a sponsor-investigator — that combined designation applies only to a natural person.

Does a sponsor-investigator have to complete their own Form 1572?

Practice varies by institution on this specific point, and it is not resolved by a single clear FDA rule referenced consistently across sources — some institutional policies require a sponsor-investigator to complete a Statement of Investigator for their own study, while other guidance treats it as unnecessary for a sponsor-investigator’s own IND since the same qualifications information is otherwise captured in the IND application itself. Research administrators should confirm the requirement with their institution’s regulatory affairs office rather than assume either answer.

Use in your systems

JATS XML <role> element

xml

<role vocab="credit"
      vocab-identifier="https://casrai.org/dictionary/"
      vocab-term="Sponsor-Investigator"
      vocab-term-identifier="https://casrai.org/dictionary/term/sponsor-investigator" />

Schema.org DefinedTerm (JSON-LD)

json

{
  "@context": "https://schema.org",
  "@type": "DefinedTerm",
  "@id": "https://casrai.org/dictionary/term/sponsor-investigator",
  "name": "Sponsor-Investigator",
  "identifier": "https://casrai.org/dictionary/term/sponsor-investigator",
  "description": "A sponsor-investigator is a specific FDA regulatory designation (21 CFR 312.3 for drugs/biologics; 21 CFR 812.3 for devices) for an individual -- never an institution, company, or group -- who both initiates a clinical investigation and actually conducts it, personally directing the administration, dispensing, or use of the investigational product to subjects. Because one person occupies both roles, that individual must independently satisfy the full set of sponsor obligations (21 CFR 312.50-312.59) and the full set of investigator obligations (21 CFR 312.60-312.70) under the same IND or IDE -- there is no reduced or merged standard for holding both roles at once.",
  "inDefinedTermSet": "https://casrai.org/dictionary/domain/compliance-regulatory#set",
  "url": "https://casrai.org/dictionary/term/sponsor-investigator",
  "sameAs": [],
  "license": "https://creativecommons.org/licenses/by/4.0/",
  "publisher": {
    "@id": "https://casrai.org/#organization"
  },
  "dateModified": "2026-07-18T11:58:50",
  "inLanguage": "en"
}